临床试验的可推广性分析:一项模拟研究
研究通过模拟一个治疗效应量为0.5(Cohen's d)、包含性别、医疗保险、合并症、年龄和动机五个协变量的患者人群,构建50个非随机临床试验,显示治疗效应偏倚范围为1.68%至99.70%。评估C统计量、标准化均数差(SMD)和Tipton推广指数(β)三个指标,发现当治疗效应偏倚从1.68%增至99.70%时,C统计量范围0.56-0.98、SMD范围0.23-11.17、β范围0.99-0.73;当偏倚<50%时,C统计量<0.86、SMD<1.95、β>0.91。基于模拟结果对现有推广指数提出建议,并附真实临床试验示例说明。
要点
- 模拟显示非随机选择患者可使治疗效应偏倚达1.68%至99.70%。
- 偏倚<50%时,C统计量<0.86、SMD<1.95、β>0.91。
- 基于模拟结果对现有推广指数提出使用建议。
核心结论
- 基于模拟结果,对现有推广指数提出使用建议。
研究设计与样本
- 模拟研究:模拟治疗效应量为0.5(Cohen's d)、含性别、医疗保险、合并症、年龄和动机五个协变量的患者人群,并构建50个非随机临床试验。
- 另提供一项真实临床试验示例作说明。
主要发现
- 50个非随机试验的相对偏倚范围为1.68%至99.70%。
- 当治疗效应偏倚从1.68%增至99.70%时,C统计量范围0.56-0.98、SMD范围0.23-11.17、β范围0.99-0.73。
- 当治疗效应偏倚<50%时,C统计量<0.86、SMD<1.95、β>0.91。
关键数值与推荐
- 治疗效应偏倚<50%对应C统计量<0.86、SMD<1.95、β>0.91。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Subjects are rarely selected on a random basis from a well-defined patient population of interest into a clinical trial, with women, children, the elderly, and those with common comorbidities who are frequently underrepresented. Decades of clinical experience have demonstrated that the application of trial findings to individual patients is permissible by using efficacy as a measure of effectiveness and assuming that the characteristics of patients are sufficiently similar. In order to investigate this issue in greater depth, we simulated a patient population with treatment effect size of 0.5 (Cohen's d) and five covariates that included gender, health insurance, comorbidity, age, and motivation. To demonstrate how selection of patients for a clinical trial can bias the results when treatment effect varies across individuals, we created 50 nonrandom clinical trials based on this patient population and showed relative bias to range from 1.68% to 99.70%. We calculated and evaluated three indexes: C-statistics, standardized mean difference (SMD), and Tipton's index (β) of generalization for the 50 nonrandom trials. Findings indicated that (i) the ranges were 0.56-0.98, 0.23-11.17, and 0.99-0.73 for C-statistics, SMD, and β, respectively, when treatment effect bias increased from 1.68% to 99.70% and (ii) C-statistics < 0.86, SMD < 1.95, and β > 0.91 when treatment effect bias <50%. Recommendations are made using existing generalization indexes on the basis of our simulation results. An example from a real clinical trial is provided for illustration. Copyright © 2017 John Wiley & Sons, Ltd.
引用
- Wang W, Ma Y, Huang Y, et al. Generalizability analysis for clinical trials: a simulation study. Stat Med. 2017. PMID: 28125858. doi:10.1002/sim.7238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。